LeBleu VS - Search Results

1

KRAS^G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8⁺ T cells.

Mahadevan KK, McAndrews KM, LeBleu VS, Yang S, Lyu H, Li B, Sockwell AM, Kirtley ML, Morse SJ, Moreno Diaz BA, Kim MP, Feng N, Lopez AM, Guerrero PA, Paradiso F, Sugimoto H, Arian KA, Ying H, Barekatain Y, Sthanam LK, Kelly PJ, Maitra A, Heffernan TP, Kalluri R. Mahadevan KK, et al. Among authors: lebleu vs. Cancer Cell. 2023 Sep 11;41(9):1606-1620.e8. doi: 10.1016/j.ccell.2023.07.002. Epub 2023 Aug 24. Cancer Cell. 2023. PMID: 37625401

2

BMP-7 functions as a novel hormone to facilitate liver regeneration.

Sugimoto H, Yang C, LeBleu VS, Soubasakos MA, Giraldo M, Zeisberg M, Kalluri R. Sugimoto H, et al. Among authors: lebleu vs. FASEB J. 2007 Jan;21(1):256-64. doi: 10.1096/fj.06-6837com. Epub 2006 Nov 20. FASEB J. 2007. PMID: 17116741

3

Structure and function of basement membranes.

LeBleu VS, Macdonald B, Kalluri R. LeBleu VS, et al. Exp Biol Med (Maywood). 2007 Oct;232(9):1121-9. doi: 10.3181/0703-MR-72. Exp Biol Med (Maywood). 2007. PMID: 17895520 Review.

4

Lymphocytes are dispensable for glomerulonephritis but required for renal interstitial fibrosis in matrix defect-induced Alport renal disease.

Lebleu VS, Sugimoto H, Miller CA, Gattone VH 2nd, Kalluri R. Lebleu VS, et al. Lab Invest. 2008 Mar;88(3):284-92. doi: 10.1038/labinvest.3700715. Epub 2008 Jan 7. Lab Invest. 2008. PMID: 18180701 Free article.

5

Stem cell-based therapy for glomerular diseases: an evolving concept.

LeBleu VS, Kalluri R. LeBleu VS, et al. J Am Soc Nephrol. 2008 Sep;19(9):1621-3. doi: 10.1681/ASN.2008070735. Epub 2008 Aug 13. J Am Soc Nephrol. 2008. PMID: 18701605 No abstract available.

6

Stem cell therapies benefit Alport syndrome.

LeBleu V, Sugimoto H, Mundel TM, Gerami-Naini B, Finan E, Miller CA, Gattone VH 2nd, Lu L, Shield CF 3rd, Folkman J, Kalluri R. LeBleu V, et al. J Am Soc Nephrol. 2009 Nov;20(11):2359-70. doi: 10.1681/ASN.2009010123. Epub 2009 Oct 15. J Am Soc Nephrol. 2009. PMID: 19833902 Free PMC article.

7

Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.

De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, Maertens O, Jeong SM, Bronson RT, Lebleu V, Kalluri R, Normant E, Haigis MC, Manning BD, Wong KK, Macleod KF, Cichowski K. De Raedt T, et al. Cancer Cell. 2011 Sep 13;20(3):400-13. doi: 10.1016/j.ccr.2011.08.014. Cancer Cell. 2011. PMID: 21907929 Free PMC article.

8

VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization.

O'Connell JT, Sugimoto H, Cooke VG, MacDonald BA, Mehta AI, LeBleu VS, Dewar R, Rocha RM, Brentani RR, Resnick MB, Neilson EG, Zeisberg M, Kalluri R. O'Connell JT, et al. Among authors: lebleu vs. Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16002-7. doi: 10.1073/pnas.1109493108. Epub 2011 Sep 12. Proc Natl Acad Sci U S A. 2011. PMID: 21911392 Free PMC article.

9

Blockade of PDGF receptor signaling reduces myofibroblast number and attenuates renal fibrosis.

LeBleu VS, Kalluri R. LeBleu VS, et al. Kidney Int. 2011 Dec;80(11):1119-21. doi: 10.1038/ki.2011.300. Kidney Int. 2011. PMID: 22083636 Free PMC article.

10

Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.

Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, Teng Y, Duncan MB, Xie L, Maeda G, Vong S, Sugimoto H, Rocha RM, Damascena A, Brentani RR, Kalluri R. Cooke VG, et al. Among authors: lebleu vs. Cancer Cell. 2012 Jan 17;21(1):66-81. doi: 10.1016/j.ccr.2011.11.024. Cancer Cell. 2012. PMID: 22264789 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

74 results

Search Page